Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

被引:277
作者
Medema, JP
de Jong, J
Peltenburg, LTC
Verdegaal, EME
Gorter, A
Bres, SA
Franken, KLMC
Hahne, M
Albar, JP
Melief, CJM
Offringa, R
机构
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands
[3] Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain
关键词
D O I
10.1073/pnas.201398198
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The concept for cellular immunotherapy of solid tumors relies heavily on the capacity of class I MHC-restricted cytotoxic T lymphocytes (CTLs) to eliminate tumor cells. However, tumors often have managed to escape from the cytolytic machinery of these effector cells. Therefore, it is very important to chart the mechanisms through which this escape can occur. Target-cell killing by CTLs involves the induction of apoptosis by two major mechanisms: through death receptors and the perforin/granzyme B (GrB) pathway. Whereas tumors previously were shown to exhibit mechanisms for blocking the death receptor pathway, we now demonstrate that they also can resist CTL-mediated killing through interference with the perforin/GrB pathway. This escape mechanism involves expression of the serine protease inhibitor PI-9/SPI-6, which inactivates the apoptotic effector molecule GrB. Expression of PI-9 was observed in a variety of human and murine tumors. Moreover, we show that, indeed, expression results in the resistance of tumor cells to CTL-mediated killing both in vitro and in vivo. Our data reveal that PI-9/SPI-6 is an important parameter determining the success of T cell-based immunotherapeutic modalities against cancer.
引用
收藏
页码:11515 / 11520
页数:6
相关论文
共 48 条
  • [1] THE CTLS KISS OF DEATH
    BERKE, G
    [J]. CELL, 1995, 81 (01) : 9 - 12
  • [2] Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
    Bird, CH
    Sutton, VR
    Sun, JR
    Hirst, CE
    Novak, A
    Kumar, S
    Trapani, JA
    Bird, PI
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) : 6387 - 6398
  • [3] The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites
    Bladergroen, BA
    Strik, MCM
    Bovenschen, N
    van Berkum, O
    Scheffer, GL
    Meijer, CJLM
    Hack, CE
    Kummer, JA
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (05) : 3218 - 3225
  • [4] T-cell recognition of melanoma antigens and its therapeutic applications
    Castelli, C
    Rivoltini, L
    Mazzocchi, A
    Parmiani, G
    [J]. INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1997, 27 (02) : 103 - 110
  • [5] CORBETT TH, 1975, CANCER RES, V35, P2434
  • [6] Davis JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO
  • [7] 2-1
  • [8] The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
    Djerbi, M
    Screpanti, V
    Catrina, AI
    Bogen, B
    Biberfeld, P
    Grandien, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) : 1025 - 1031
  • [9] Fenton RG, 1998, CANCER RES, V58, P3391
  • [10] CELL LINE FROM AN INDUCED CARCINOMA OF MOUSE RECTUM
    FRANKS, LM
    HEMMINGS, VJ
    [J]. JOURNAL OF PATHOLOGY, 1978, 124 (01) : 35 - &